| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |